艾德生物(300685) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥195,164,302.80, a decrease of 5.28% compared to ¥206,049,845.51 in the same period last year[6] - Net profit attributable to shareholders was ¥57,317,259.24, representing an increase of 6.91% from ¥53,614,836.90 year-on-year[6] - Basic earnings per share for the period was ¥0.14, up 7.69% from ¥0.13 in the previous year[6] - Total operating revenue for Q1 2023 was ¥195,164,302.80, a decrease of 5.8% compared to ¥206,049,845.51 in Q1 2022[20] - Net profit for Q1 2023 was ¥57,317,259.24, representing an increase of 7.4% from ¥53,336,627.60 in Q1 2022[22] - Basic and diluted earnings per share for Q1 2023 were both ¥0.14, up from ¥0.13 in the same period last year[23] Cash Flow - The net cash flow from operating activities surged by 141.62% to ¥67,559,006.96, compared to ¥27,961,142.84 in the previous year[6] - Cash inflows from operating activities totaled $231,654,038.82, compared to $198,916,694.38 in the prior period, indicating an increase of about 16.5%[24] - Cash outflows from operating activities decreased to $164,095,031.86 from $170,955,551.54, reflecting a reduction of approximately 4.7%[24] - The net cash flow from investing activities was negative at -$88,181,521.96, compared to -$140,286.55 in the previous period, showing a significant improvement[25] - The net cash flow from financing activities was -$13,392,007.96, an improvement from -$17,034,520.27 in the previous period, indicating a reduction in cash outflow by about 21.5%[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,671,421,950.98, reflecting a 1.24% increase from ¥1,650,924,910.62 at the end of the previous year[6] - The total current assets at the end of the first quarter amounted to ¥1,306,200,106.03, an increase from ¥1,285,141,149.89 at the beginning of the year, reflecting a growth of approximately 1.8%[17] - Total liabilities decreased to ¥126,695,415.85 from ¥151,197,385.37, a reduction of 16.2%[19] - The company reported a significant increase in other non-current assets by 55.78% to ¥12,884,143.57, primarily due to increased equipment procurement prepayments[10] Shareholder Information - The total number of shares held by the top 10 unrestricted shareholders is 299,000,000 shares, with the largest shareholder holding 87,701,616 shares, accounting for 22.03%[13] - The company has a total of 607,499 shares under lock-up at the end of the period, with 37,969 shares newly restricted[15] Government Support and Investments - The company received government subsidies amounting to ¥11,895,115.39, a significant increase of 399.63% compared to ¥2,380,790.56 in the previous year[10] - The company’s investment income showed a loss of ¥1,486,582.20, a decline of 183.77% due to losses from joint ventures[10] - Research and development expenses for Q1 2023 were ¥36,988,744.69, slightly down from ¥38,760,861.03 in Q1 2022[20] Management Outlook - The company is focused on expanding its market presence and developing new products, although specific figures were not disclosed in the report[15] - The management indicated a positive outlook for the upcoming quarters, emphasizing strategic investments and potential acquisitions to enhance growth[15]